Last Updated: November 16, 2026

Details for Patent: 8,648,097

« Back to Dashboard


Summary for Patent: 8,648,097
Title:Pyridylaminoacetic acid compound
Abstract:The present invention provides a novel pyridylaminoacetic acid compound represented by the following formula (1): (wherein R1, R2, R3, Y and Z are as defined in the description and claims), or a pharmacologically acceptable salt thereof. The pyridylaminoacetic acid compound has EP2 agonistic action and is therefore useful as a therapeutic and/or prophylactic agent for respiratory diseases such as asthma or chronic obstructive pulmonary disease.
Inventor(s):Ryo Iwamura, Masayuki Tanaka, Tetsushi Katsube, Manabu Shigetomi, Eiji Okanari, Yasunori Tokunaga, Hiroshi Fujiwara
Assignee: Ube Corp
Application Number:US12/922,028
Patent Claim Types:
see list of patent claims
Composition; Compound;
Patent landscape, scope, and claims:

United States Drug Patent 8,648,097: Claim Scope, Exclusivity, Litigation and Patent Landscape

U.S. Patent No. 8,648,097 protects a broad genus of pyridylaminoacetic acid compounds and their pharmacologically acceptable salts, with narrower claims directed to specific aryl-pyrazole and substituted pyridyl structures. Claim 15 extends protection to pharmaceutical compositions containing a claimed compound. The patent does not, from the supplied claims alone, identify an approved drug, an International Nonproprietary Name, an Orange Book-listed product, or a commercial licensee.

The core commercial risk is compound-level infringement. A product may fall within the patent if it contains the claimed pyridylaminoacetic acid architecture, the specified sulfonylaminomethyl-linked aryl-pyrazole group, and a permitted pyridyl substitution pattern. The claims do not require a particular therapeutic indication, formulation, dosage strength, or manufacturing process.

What does U.S. Patent 8,648,097 protect?

The patent protects four related subject-matter categories:

Protected subject matter Principal claims Scope
Chemical compounds 1-14 Pyridylaminoacetic acid compounds and pharmacologically acceptable salts
Substituted analogues 2-13 Narrower alkyl, aryl, pyrazolyl and pyridyl limitations
Named chemical species 14 Four expressly identified acid, ester and pyridyl compounds
Pharmaceutical compositions 15 Compositions containing a claim 1 compound or salt plus conventional excipients

Claim 1 is the principal genus claim. It covers compounds having:

  • A pyridylaminoacetic acid core;
  • R1, R2 and R3 independently selected from hydrogen or specified alkyl groups;
  • A Y substituent defined as an arylene-pyrazolyl group;
  • A Z substituent defined as a substituted pyridyl group; and
  • The corresponding pharmacologically acceptable salts.

The claims are composition-of-matter claims. They do not depend on a particular biological mechanism, disease indication or clinical use.

What structural elements are required?

The claim set requires the combination of several structural components rather than any isolated substituent:

  1. A pyridyl ring bearing the aminoacetic acid-related substituent.
  2. An arylene linker, narrowed to phenylene in claims 5 and 6.
  3. A pyrazolyl group attached to that arylene linker.
  4. A second pyridyl group, designated Z, with specified optional substituents.
  5. Defined alkyl substitution around the aminoacetic acid portion.
  6. The free acid or an acceptable salt, with claim 14 expressly identifying ester examples.

The supplied claim language contains apparent drafting or transcription errors. Claim 5 states “wherein Y a -Q1-Q2 group,” claims 10 and 12 refer to “a 4 (pyrazol-1-yl)phenyl” rather than a fully punctuated structural definition, and claims 12 and 13 are substantively duplicated. The issued patent, its drawings and the prosecution history should control over a text transcription when assessing enforceability or infringement.

How broad is independent claim 1?

Claim 1 is materially broader than the later claims because it permits:

  • R1, R2 and R3 to be hydrogen or C1-C6 alkyl;
  • Any arylene group for Q1;
  • A broad set of pyrazolyl substituents for Q2;
  • Broad substituted pyridyl groups for Z; and
  • Pharmacologically acceptable salts.

The claim does not require the preferred 4-(pyrazol-1-yl)phenyl arrangement. That narrower structure appears in claims 5, 6 and the later species claims.

The claim also does not require a particular stereochemical configuration based on the supplied language. If the claimed molecular framework contains stereogenic centers, the absence or presence of an express stereochemical limitation would affect the reach of the claim and should be determined from the issued claim text and specification.

What substituents are covered?

The permitted substituents include:

Region Broad claim 1 scope Narrower scope in dependent claims
R1-R3 Hydrogen or C1-C6 alkyl C1-C4 alkyl; ultimately hydrogen or methyl in several claims
Q2 pyrazolyl group Halogen, hydroxy, C1-C6 alkyl, halogenoalkyl, alkoxy or halogenoalkoxy Enumerated C1-C4 groups and specific fluorinated or chlorinated examples
Z pyridyl group Halogen, C1-C6 alkyl, halogenoalkyl, alkoxy or halogenoalkoxy Specific fluorine, chlorine, bromine, alkyl, methoxy and fluoromethoxy variants

Claim 6 enumerates particular pyrazolyl substituents, including methyl, ethyl, propyl, isopropyl, tert-butyl, trifluoromethyl, difluoromethyl, methoxy, ethoxy, tert-butoxy, trifluoromethoxy and related halogenated groups.

Claims 7 and 9 narrow the Z pyridyl substituent to listed halogen, alkyl, alkoxy and halogenated groups. Claim 9 is particularly relevant to freedom-to-operate analysis because it limits Z to a pyridyl group substituted by a halogen or C1-C4 alkoxy group.

What compounds are expressly covered by claim 14?

Claim 14 identifies four compounds:

  1. (6-{4-(pyrazol-1-yl)benzylaminomethyl}pyridin-2-ylamino)acetic acid;
  2. (6-{4-(pyrazol-1-yl)benzylaminomethyl}pyridin-2-ylamino)acetic acid;
  3. The corresponding ethyl ester of the pyridin-3-ylsulfonyl compound; and
  4. The corresponding isopropyl ester.

These species are narrower than the genus in claim 1 and are important for product-specific validity and infringement analysis. A commercial candidate matching one of these structures would face direct literal-claim exposure unless the claim is invalidated, disclaimed, expired or otherwise unenforceable.

The claim 14 language also creates a construction issue. The named compounds contain a 4-(pyrazol-1-yl)benzyl group, while portions of claims 10-13 refer to a 4-(pyrazol-1-yl)phenyl group. The distinction between phenyl and benzyl is chemically material. The issued patent and prosecution record should be used to determine whether this reflects a transcription defect, an intentional distinction, or an antecedent structural definition elsewhere in the patent.

How many patents cover the disclosed chemical series?

Based on the supplied material, one U.S. patent is identified: U.S. Patent No. 8,648,097. The claim text alone does not establish whether related continuation, divisional, continuation-in-part, foreign, or terminal-disclaimer patents exist.

A complete patent-family analysis would normally separate the following layers:

Patent layer Relevance to this compound series
Priority and national-stage filings Establish earliest effective filing date and geographic family
Continuations or divisionals May contain narrower surviving claims after prosecution
Composition-of-matter patents Primary barrier for the active compound
Salt, polymorph or crystalline-form patents May create later-expiring barriers
Formulation patents May affect specific dosage forms or delivery systems
Method-of-use patents May restrict treatment of a defined disease
Process patents May restrict manufacturing routes but often do not block alternative synthesis
Regulatory exclusivity May operate independently of patent rights

The supplied claims establish composition and pharmaceutical-composition protection. They do not establish separate formulation, method-of-use, polymorph, salt-selection or manufacturing claims.

When does U.S. Patent 8,648,097 lose exclusivity?

The patent number indicates issuance in 2014, but the expiration date cannot be calculated reliably from the claims alone. U.S. patent term generally depends on:

  • The earliest effective nonprovisional or international filing date;
  • Patent-term adjustment;
  • Patent-term extension under 35 U.S.C. § 156;
  • Terminal disclaimers;
  • Any applicable patent-term adjustment certificate; and
  • Whether the patent claims priority to an earlier application.

The relevant term is not normally measured from the 2014 issue date. A 20-year term is generally measured from the earliest effective U.S. nonprovisional filing date, subject to statutory adjustments. A definitive expiration date therefore requires the patent’s front page, priority chain and USPTO term data.

Exclusivity timeline

Event Status from supplied record
Earliest priority filing Not provided
U.S. application filing Not provided
U.S. patent issuance Patent No. 8,648,097; issued in 2014 based on the patent number and standard numbering chronology
Patent-term adjustment Not provided
Patent-term extension Not established
Terminal disclaimer Not established
Expected expiration Not determinable from the claims alone
FDA regulatory exclusivity No product or FDA approval identified
Orange Book listing No listing established

A patent expiration date should not be inferred from the issuance date. The date controls generic-entry timing only after the patent family and statutory term are confirmed.

What is the Orange Book status of U.S. Patent 8,648,097?

No Orange Book status can be assigned from the supplied claim set because no approved drug product, active ingredient, New Drug Application holder or reference-listed drug is identified.

The patent claims are directed to chemical compounds and a pharmaceutical composition. That type of claim can be eligible for Orange Book listing if it claims an approved drug substance, drug product or method of use and is properly submitted by an NDA holder. But patent eligibility for listing is product-specific. A compound patent is not automatically an Orange Book patent.

For a generic applicant, the principal regulatory pathways would be:

  • Paragraph IV certification if the patent is listed and the applicant asserts that it is invalid, unenforceable or not infringed;
  • Paragraph III certification if the applicant accepts delayed launch until patent expiry;
  • A section viii statement for a listed method-of-use patent where the applicant omits the protected indication; or
  • An ANDA without a certification if no applicable patent is listed.

No Paragraph IV challenge, ANDA, 30-month stay, Abbreviated New Drug Application litigation or settlement agreement is identified in the supplied record.

What formulation patents are protected?

Claim 15 is a broad pharmaceutical-composition claim. It covers a composition containing a claim 1 compound or salt and one or more conventional additives, including:

  • Vehicles;
  • Lubricants;
  • Binders;
  • Disintegrators;
  • Emulsifiers;
  • Stabilizers;
  • Corrigents; and
  • Diluents.

This is not a detailed dosage-form claim. It does not expressly require a tablet, capsule, injectable formulation, controlled-release matrix, enteric coating, nanoparticle, liposome, transdermal system or specific excipient ratio.

Claim 15 may therefore be vulnerable to validity and construction challenges if read broadly against routine pharmaceutical formulation practice. Its practical value depends on the validity of claim 1 and whether the marketed composition contains a claimed compound or salt. It does not independently protect an unclaimed active ingredient merely because the product contains ordinary excipients.

Are method-of-use patents or manufacturing patents covered?

The supplied claims do not contain a method-of-use claim. There is no claim directed to:

  • Treating a particular disease;
  • Modulating a named biological target;
  • Administering a defined dose;
  • Selecting a patient population;
  • Combining the compound with another therapy; or
  • Preventing or reducing a specified clinical endpoint.

The claims also do not define a synthetic process. They do not recite reaction conditions, starting materials, catalysts, solvents, purification steps or crystallization parameters.

The principal barrier is therefore the active compound itself. An alternative manufacturing route would not avoid infringement if the resulting product falls within an asserted composition claim. Conversely, a process patent would be necessary to create a separate route-based barrier.

How strong is the patent estate?

The disclosed estate has moderate apparent breadth at the composition level, but its commercial strength cannot be ranked conclusively without the prosecution history and related-family claims.

Strengths

  • Claim 1 covers a structurally defined genus rather than only one compound.
  • The claim includes pharmacologically acceptable salts.
  • Claims 5-13 preserve preferred subgenera around the phenylene-pyrazole and substituted pyridyl architecture.
  • Claim 14 identifies specific compounds that may provide focused enforcement targets.
  • Claim 15 links the chemical genus to pharmaceutical compositions.

Limiting factors

  • The claim scope is restricted to a particular chemical scaffold.
  • No method-of-use or process claims are shown.
  • No formulation specificity is present beyond conventional excipients.
  • The supplied language contains apparent duplication and drafting defects.
  • The patent’s remaining term is not established.
  • No commercial product or regulatory indication is identified.
  • The validity of the genus depends on written description, enablement, novelty and inventive-step or obviousness support across the claimed chemical breadth.

Potential invalidity pressure points would include prior-art compounds containing the same pyridylaminoacetic acid core, aryl-pyrazole linkage and sulfonylaminomethyl arrangement; genus breadth relative to the examples; and whether the specification enables the full range of substitutions recited in claim 1.

Which companies are challenging the patent?

No challenger, ANDA filer, district-court action, International Trade Commission investigation or settlement agreement is identified in the supplied material.

A company developing a close analogue would face two distinct questions:

  1. Whether the candidate literally satisfies every limitation of claim 1 or a narrower surviving claim.
  2. Whether the candidate is materially different but still vulnerable under the doctrine of equivalents.

The most important design-around variables are the identity and attachment position of the pyridyl group, the arylene-pyrazolyl linkage, the sulfonylaminomethyl arrangement, and the substitution pattern around the aminoacetic acid portion.

How does this patent affect generic and follow-on entry?

This is not a conventional generic-entry case unless the claimed compound corresponds to an approved small-molecule drug. If no reference-listed drug exists, an ANDA strategy may not be available. A sponsor might instead pursue:

  • A full NDA under section 505(b)(1);
  • A 505(b)(2) application if reliance on existing information is appropriate;
  • A novel chemical entity strategy if the compound has no approved reference product; or
  • Development of a non-infringing analogue.

Biosimilar risk is not relevant to the patent as presented. The claims cover small-molecule chemical compounds, not a biologic, protein, antibody or biosimilar reference product. A biosimilar pathway under the Public Health Service Act would not ordinarily apply.

What licensing and revenue exposure can be established?

No licensing agreement, assignment, royalty arrangement, milestone package or collaboration is identified by the supplied claims. No revenue exposure can be calculated because the record does not identify:

  • A marketed product;
  • An approved indication;
  • Annual sales;
  • A patent holder’s product portfolio;
  • A licensee;
  • An NDA holder; or
  • A competing generic.

The commercial value of the patent is therefore contingent on whether one of the claimed compounds became a clinical or commercial candidate. The patent alone does not establish product revenue.

Key Takeaways

  • U.S. Patent 8,648,097 is directed primarily to pyridylaminoacetic acid compounds and pharmacologically acceptable salts.
  • Claim 1 is the principal broad genus claim.
  • Claims 5-13 narrow the invention toward phenylene-pyrazole and selected substituted pyridyl structures.
  • Claim 14 expressly identifies four chemical species, including acid and ester forms.
  • Claim 15 covers pharmaceutical compositions containing a claim 1 compound or salt with conventional excipients.
  • No method-of-use, manufacturing-process, polymorph or detailed formulation claims appear in the supplied text.
  • No approved drug, Orange Book listing, Paragraph IV challenge, litigation, settlement or license is identified.
  • The patent expiration date cannot be determined from the claims or patent number alone.
  • The strongest freedom-to-operate issue is whether a candidate compound contains the claimed pyridylaminoacetic acid, aryl-pyrazole and substituted pyridyl architecture.
  • Claim 13 appears substantively duplicative of claim 12, while claims 10-12 and 14 contain terminology that should be checked against the issued patent and prosecution record.

FAQs

Does U.S. Patent 8,648,097 claim a specific drug name?

No drug name or International Nonproprietary Name appears in the supplied claims. The patent claims chemical structures and a pharmaceutical composition.

Can a salt of a claimed compound avoid infringement?

Not ordinarily if the salt is a pharmacologically acceptable salt covered by claim 1. The salt limitation is expressly included in the claims.

Does claim 15 cover every tablet containing a pyridylaminoacetic acid compound?

No. It requires a compound or salt within claim 1 and one or more listed pharmaceutical additives. It does not independently cover unrelated pyridylaminoacetic acid compounds.

Is a 505(b)(2) application automatically blocked by this patent?

No. Regulatory pathway and patent infringement are separate issues. A 505(b)(2) applicant would need to assess the specific active ingredient, listed patents and any applicable composition or use claims.

Does the patent create biosimilar entry risk?

No meaningful biosimilar risk is indicated. The claims concern small-molecule chemical compounds rather than biologic products.

References

  1. United States Patent No. 8,648,097, claims 1-15. (2014). U.S. Patent and Trademark Office.

  2. U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term information. https://www.uspto.gov

  3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

  4. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions and patent certifications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/anda-submissions-resources

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 8,648,097

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ocuvex Therap OMLONTI omidenepag isopropyl SOLUTION;OPHTHALMIC 215092-001 Sep 22, 2022 RX Yes Yes 8,648,097 ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,648,097

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009224329 ⤷  Start Trial
Canada 2718393 ⤷  Start Trial
China 101970410 ⤷  Start Trial
China 103965099 ⤷  Start Trial
Cyprus 1121543 ⤷  Start Trial
Denmark 2264009 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.